(Photo Courtesy: www.corp.izea.com)
The systemic sclerosis treatment market will expand from just under $316 million in 2014 to approximately $500 million by 2024, representing a modest Compound Annual Growth Rate (CAGR) of 4.7%, says research and consulting firm GlobalData.
Systemic sclerosis pathophysiology is complex and incompletely understood.
Treatment varies by patient and aims to address complications, but no single therapy targets the underlying disease mechanism.
According to the company's latest report, this rise, spread across the seven major markets of the US, Italy, France, the UK, Spain, Germany, and Japan, will be driven by a number of factors, including an increased use of expensive biologics, and off-label use of therapies to treat the disease.
As such, Dr Heather Leach, GlobalData's Managing Analyst covering Immunology, states that while the systemic sclerosis treatment market will see some growth by 2024, unmet needs will not be completely addressed.